Pulmatrix Secures $14,000,000 Series B Funding
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=cdde41b5-0245-4c47-85f4-5286a17ef4da&Preview=1 -
Date
8/15/2011 -
Company Name
Pulmatrix -
Mailing Address
99 Hayden Avenue Lexington, MA 02421 -
Company Description
Pulmatrix Inc. is a pharmaceutical company developing inhalable aerosols and enabling technologies that help control respiratory infectious disease and human-source airborne contamination. -
Website
http://www.pulmatrix.com -
Transaction Type
Venture Equity -
Transaction Amount
$14,000,000 -
Transaction Round
Series B -
Proceeds Purposes
Proceeds from the financing will enable Pulmatrix to accelerate its lead iCALM drug candidate, PUR118, through Phase 2A efficacy studies in two diseases, chronic obstructed pulmonary disease (COPD) and cystic fibrosis (CF). -
M&A Terms
-
Venture Investor
Polaris Venture Partners -
Venture Investor
5AM Ventures -
Venture Investor
ARCH Venture Partners -
Venture Investor
Novartis BioVenture Fund
